Market capitalization | $2.23b |
Enterprise Value | $1.82b |
P/E (TTM) P/E ratio | 8.64 |
EV/FCF (TTM) EV/FCF | 9.97 |
EV/Sales (TTM) EV/Sales | 4.20 |
P/S ratio (TTM) P/S ratio | 5.13 |
P/B ratio (TTM) P/B ratio | 3.28 |
Revenue growth (TTM) Revenue growth | 624.06% |
Revenue (TTM) Revenue | $434.43m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 434 434 |
624%
624%
|
|
Gross Profit | 431 431 |
661%
661%
|
|
EBITDA | 256 256 |
383%
383%
|
EBIT (Operating Income) EBIT | 253 253 |
370%
370%
|
Net Profit | 275 275 |
449%
449%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Head office | United States |
CEO | Dinesh Patel |
Employees | 126 |
Founded | 2006 |
Website | www.protagonist-inc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.